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Abstract

lntroduction

The control of the formation of crystals in
biological fluids is one of the most exciting field of
research involving both organic and biochemical
areas. Many organisms have evolved mechanisms
which minimize or avoid the effects of nucleation and
crystal growth formation. One of the most important
mechanism is the interaction of specific proteins, called
inhibitors, with crystals which alters their habits and
leads to their elimination. This article, focused on
saliva, pancreatic juice and bile, reviews our present
knowledge on the structure-function relationships
existing between these proteins and their ability to
inhibit the growth of different calcium salt crystals.

In mammals,
many biological
fluids are
supersaturated with respect to calcium salts, which are
carbonate in pancreatic juice and bile, phosphate in
saliva and mainly oxalate in urine. Supersaturation is
essential since these minerals are involved in the
construction of skeletal material, the process of teeth
mineralization or even specific adsorption to tissues.
But it also means that calcium salts crystals will
spontaneously form and grow in those fluids. That is
why these mineralization processes have to be
controlled in order to avoid precipitation (nucleation),
growth and finally aggregation of crystals which might
induce cell injury or result in the clogging of the ducts
through which secretion flows. For that purpose,
organisms developed sophisticated mechanisms
controlling the deposition of minerals in biological
tissues. Several small organic and inorganic
molecules have been shown to inhibit nucleation or
crystal growth. Now it is clear that in most biological
fluids, several proteins fulfill the physiological role of
repressing formation, growth and aggregation of
calcium crystal salts. The purpose of this paper is not to
review the evidence documenting the role of proteins
in the control of crystal growth, but to describe the most
recent data on the relationship between structure and
function of these inhibitors in saliva, bile and
pancreatic juice. The main properties of these protein
inhibitors are summarized in Table 1.

Protein Inhibitors

Inhibitorsin saliva
Human salivary secretion is supersaturated with
respect to calcium phosphate (CaP) salts which are
involved in the formation of the dental enamel.
Supersaturation is quite important in the stabilization
and protection of enamel and for recalcification after
demineralization by bacteria (Feagin et al., 1971). Yet,
supersaturation should not result in an excess of
calcium phosphate precipitation. Early studies on
calcium phosphate precipitation in saliva showed that it
was unexpectedly delayed compared to precipitation
from equivalent synthetic solutions (Rathje, 1956). In
addition, macromolecular fractions isolated from
human salivary
secretions
strongly
inhibited
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Table 1. Main characteristics of protein inhibitors in saliva, pancreatic juice and bile.
Fluid

Family

name

Statherins

Length
(aminoacid
residues)a

Proteins

Statherin (main form),
Statherin SV1, SV2, SV3
(Jensen et al., 1991)

main form (43)

Inhibition
of
nucleation
(spontaneous
precipitation)
CaP
(Hay et al.,
1979;
Oppenheim
et al., 1986)

Inhibition
of
crystal growth
(secondary
precipitation)
CaP
(Hay et al.,
1979;
Oppenheim
et al., 1986)

CaCO3
(Hay et al.,
1986)
Acidic
Praline-RichProteins

SALIVA

PRP-1= Protein C,
PRP-3= Protein A,
PRP-2, PRP-4, PIF-s,
PIF-f
(Wong and Bennick,
1980;
Schlesinger and Hay,
1979, 1986;
Wong et al., 1979;
Maeda et al., 1985)
CCP1=SA-I, S (and S1,
S2)b=C1 (and C2,
C3)=SAP-1, HSP-12=SAIll, SA, SN

Type II
Cystatins
or
CysteineContaining
(AI-Hashimi et al., 1988;
Phospholsemura et al., 1984,
proteins (CCP) 1991;
Shomers et al., 1982a,
Lamkin et al., 1991)
Histatin1 (neutral HRP)
Histatins or
=HRP=HRP-1 =PPb
Histidine-rich
Histati n2=p hosphory lated
form of Histatin1
polypeptides
(HRP)
(Oppenheim eta!., 1986,
1988; Peters and Azen,
1977; Baum et al., 1977;
Azen, 1978; Sabatini and
Azen, 1989)

PANCREATIC
JUICE

Pancreatic Lithostathine

PRP-1 and PRP-2
(150),
PRP-3 and PRP-4
(106),
PIF-s (150),
PIF-f (106)

CaCO3
(Saitoh et al.,
1985;
Hay et al.,
1986)

CCP1=SA-I (121), ?
SN (113),
SA (121).
S=SAP-1 (113),
HSP-12=SA-III
(121)

CaP
(Hay et al.,
1979; 1984;
Moreno et al.,
1979;
Oppenheim et
al., 1986)

CaP:
Cystatins S, S1,
SN:
(hydroxyapatite;
Johnsson et al.,
1991 a)
CCP(DCPOC
assay; Shomers
et al., 1982b)

HRP (38)

inactive for
CaP
(Oppenheim
et al., 1986)

CaP
(Oppenheim et
al., 1986)

main form (144)

CaCO3
(Bernard
et al., 1992)

CaCO3
(Bernard
et al., 1992)

CaCO3 (Okido
CaCO3
(Shimizu et al., et al., 1992)
1989;
Oki do et al.,
1992)
?:
. u nkn own o r not tested,· a: wi t houts ignal pept ide,. b. . phosphorylated forms of S
(see also text); c : see Hay and Gron (1976)
BILE

APF/CBP/CRP, all
probably identical

?
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Other properties

1) boundary lubricant of
human saliva (Douglas et al.,
1991)

Gene cloning

Remarks

Sabatini et al.,
1990

chromosomal
localization :
4q11-13
(Sabatini et al., 1987)

O'Hanlon et al.,
1989

possible role in
tasting (Azen et al.,
1990)

SA and SN
(Saitoh et al.,
1987; Saitoh et
a/., 1991)

present in many body
fluids
(Lamkin et al., 1991)

probably
encoded by two
genes Pb and
PPb

only present in
salivary tissues
(Sabatini et al., 1989)

2) promotes attachment of
bacteria to apatitic surfaces
(Gibbons and Hay, 1988;
Gibbons et al., 1988)

Hay et al. (1982),
Bennick et al.
( 1981)

Maeda et al.,
1985
Bennick, 1987

PRP-1 and PRP-3 :
ca2+-binding sites
(Bennick, 1976,
1977)
?

2) promote attachment of
bacteria to apatitic surfaces
(Gibbons and Hay, 1988;
Gibbons et al., 1988)
SA-I
(AI-Hashimi et al.,
1988);
Sand SN
(Bobek et al.,
1991)

?

1) constituents of the enamel
pellicle (Kousvelari et al.,
1980)

Sabatini and
Azen, 1989

No

Giorgi eta!., 1989

highly suspected
(Shimizu et al.,
1989)

No

1) strong binding to
hydroxyapatite (Shomers et
al., 1982b, Johnsson et al.,
1991 a)
2) cystatin SN : constituent of
the enamel pellicle (AlHashimi and Levine, 1989)
3) potential anti-bacterial
activity (Obenauf et al., 1984)
1) antibacterial and antifungal
activities (MacKay et al.,
1984; Oppenheim et al.,
1986, 1988: Xu et al., 1991)
2) H RPs 1-2 : effects on
aggregation and viability of
some bacteria strains (Payne
eta!., 1991)
3) histatin levels increased in
AIDS patients (Atkinson et al.,
1990)

(Azen et al.,
1978, Peters
and Azen, 1977)

Watanabe et al.,
1990

1) promoter of cholesterol
precipitation (Domingo et al.,
1992)
2) tighly bound to bilirubin
(Shimizu et al., 1989;
Martigne et al., 1985)
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attempts have been made to localize the active
segments of statherin in both inhibition of nucleation
and precipitation of calcium phosphate crystals.
Removal of the carboxy-terminal half of the molecule
resulted in a 75% reduction of its ability to inhibit
nucleation, but did not affect its ability to inhibit crystal
growth. Surprisingly, removal of residues 10-18 and 718, leaving intact both amino-terminal phosphoserines,
considerably enhanced inhibition of crystal growth
compared to the parent molecule. This function
appears entirely localized to the NH2-terminal portion
of the molecule. This could be explained by the fact
that smaller fragments have a better access to growth
sites and are more easily adsorbed onto crystal
surfaces. Conversely, the inhibitory activity of the NH2terminal segments, resulting from protease cleavage,
on spontaneous precipitation from supersaturated
solution is reduced compared to the parent molecule.
This suggests that the carboxy-terminal segment plays
an important role in the inhibition of nucleation,
probably by stabilizing the interactions with embryo
crystals since, by itself, it is without activity (Hay et al.,
1979). In order to assess the importance of the
phosphoserines, Schlesinger and coworkers (1987)
synthesized
the
dipeptide
phosphoserylphosphoserine. It was shown to substantially inhibit
both nucleation and crystal growth, although less than
the parent molecule. These first attempts to correlate
structure and function were recently completed by
systematic analysis. For this purpose, Raj et al. ( 1992)
synthetized several fragments of statherin. They
showed first that aspartic acid residues were very
important in binding and crystal growth inhibition, more
than phosphoserines. Moreover, they found a good
correlation between the possible alpha-helix structures
of acidic NH2-terminal fragments and their capacity to
bind hydroxyapatite (HAP) surfaces. As shown by
circular dichroism experiments, the central and COOHterminal fragments appear more flexible, adopting
different conformations depending on the solvent. This
might reflect the adaptability of the molecule to different
physiological conditions which optimizes orientation of
the NH2-terminal part towards the growth faces of the
crystals.
The acidic proline-rich-proteins
(PRPs\. Amino
acid analysis of human total salivary proteins revealed
an unusual content in praline (up to 33%) of total
amino acids (Leach et al., 1967). The fact that amylase,
which accounts for more than 30% of parotid and
submandibular
secretory proteins, contains few
pralines, led some authors to investigate the proteins
with a high content of praline which were referred to as
proline-rich-proteins (PRPs). This superfamily can be
divided into three groups : glycosylated, basic and
acidic-PRPs (Mandel et al., 1965; Bennick, 1975;
Levine and Keller, 1977). Some members may also be
phosphorylated. Within these groups, binding to HAP
and inhibition of calcium phosphate precipitation are
only associated with acidic-PRPs (Hay, 1973; Bennick
and Cannon, 1978). Although these proteins strongly
inhibit crystal growth of calcium phosphate, they do not
inhibit nucleation, contrary to statherin (Hay et al.,
1979; Moreno et al., 1979; Hay et al., 1984;
Oppenheim
et al., 1986).
Since saliva
is

Abbreviations

APF : Anionic-Polypeptide
Fraction; CaC03 :
Calcium carbonate; CaP : Calcium phosphate; CBP :
Calcium-Binding Protein; CCP : Cysteine-Containing
Phosphoprotein
or Cystatin;
CRP : CalciumRegulatory Protein; DCPD : Dicalcium phosphate
dihydrate; HAP : Hydroxyapatite; kb : kilobase; kDa :
Kilodalton; Mr: Molecular weight; PRP: Praline-Rich
Protein; PSe : Phosphoserine;
PSP : Pancreatic
Stone Protein; SOS-PAGE : Sodium Dodecyl-SulfatePolyacrylamide Gel Electrophoresis.
precipitation from supersaturated calcium phosphate
solutions (Gron and Hay, 1976). This is essentially due
to the presence of at least four types of proteins in both
parotid and submandibular gland secretion : prolinerich-proteins, statherins, cystatins and histatins. These
four groups of salivary proteins are members of
superfamilies of related proteins which have evolved
by different splicings or post-translational processings.
The first two are well-kown proteins, studied for more
than 20 years, whereas the discovery of the inhibitory
activity of the two last ones is more recent.
The statherins. Statherin, from the greek
statheropio,
meaning "to stabilize",
has been
investigated and purified by Hay ( 1973). The first
observations on human statherin showed that it
adsorbed selectively onto hydroxyapatite and dental
enamel and was by far the most abundant protein
found in hydroxyapatite-adsorbed fractions from saliva
(Hay,
1973).
Statherin
is constituted
by a
heterogeneous
population
since
sequential
chromatography of hydroxyapatite-adsorbed salivary
proteins resulted in the purification of several statherin
variants. It was eventually shown that multiple forms
of
statherin
derived
from
post-translational
modifications and/or alternative splicing of a single
gene (Jensen et al., 1991). The biological significance
of these variants is not understood. The parent
molecule is a phosphoprotein of 43 amino acid
residues with a molecular weight of 5380, and an
acidic isoelectric point of 4.22. A striking feature is its
unusual amino acid composition: 25% are acidic
residues (aspartate and glutamate), 25% are aromatic
residues, mainly tyrosine, and praline accounts for
16% of amino acids (Schlesinger and Hay, 1977).
Furthermore, its sequence shows that five of the six
negatively charged residues occur in the NHrterminal
peptide while the carboxy-terminal two-third of the
protein is quite uncharged and relatively hydrophobic
(Schlesinger and Hay, 1977).
At physiological
concentrations,
statherin is able to inhibit crystal
growth and nucleation of calcium phosphate salts,
unlike praline-rich-proteins
(Schlesinger and Hay,
1977; Hay et al., 1979). The detailed mechanisms by
which statherin (or other proteins) inhibit nucleation is
not well understood. It is generally believed that the
protein binds to the first embryo crystals, thereby
delaying precipitation. In some cases, the formation of
these crystals is rate limiting, especially in the case of
calcium phosphate precipitation (which facilitates the
arrest of ttiP.ir growth). Because of the peculiar
distribution of amino acids in its sequence, many
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supersaturated with respect to calcium phosphate
salts, it has been proposed that they prevent unwanted
deposition of these salts onto tooth surfaces by
adsorbing to calcium phosphate surfaces, providing a
protective and reparative environment to dental
enamel (Hay et al., 1979). Four acidic proteins have
been isolated and named PRP1-4 (Oppenheim et al.,
1971). At the same time, other investigators
independently
described the acidic-proline-rich
proteins and named them differently which resulted in
a certain confusion. The primary structures of these
four proteins have been reported : PRP-1 which is
identical to Protein C (Wong and Bennick, 1980), PRP2 (Schlesinger and Hay, 1986), PRP-3 which is
identical to Protein A (Wong et al., 1979), and PRP-4
(Schlesinger and Hay, 1979). PRP-1 and.-2 are
composed of 150 residues, their sole difference being
that residue 4 is Asn in PRP-1 and Asp in PRP-2
(Schlesinger et al., 1977). Similarly PRP-3 and -4 are
composed of 106 residues, which are identical to the
106 NH2-terminal amino acids of PRP-1 and PRP-2
respectively and probably derive from them by posttranslational modification (Karn et al., 1979; Wong et
al., 1983). In addition, Maeda and coworkers (1985)
reported the cDNA sequence of two acidic-PRPs, PIF-s
and PIF-f. PIF-s is identical to PRP-1 and PIF-f to PRP-3
except that they present with an inversion between
amino acids 4 and 50. Messenger RNA splicing and
post-translational cleavage must have been involved.
This is strenghtened by the results obtained by Maeda
et al. (1985) suggesting that the entire family of PRP is
coded only by six loci which might have diverged
during evolution. The biological significance of these
differences is not yet known. As for statherin, the
primary structures of acidic-PRPs revealed a number of
striking features, particularly a high degree of structural
charge asymmetry. In spite of primary sequences
similarities, PRPs display some differences in their
adsorption onto apatic surfaces. For instance, Moreno
et al. (1982) reported that PRP-1 has a higher affinity
constant for HAP than PRP-2. A well-studied example
is given by PRP-1. The NH2-terminal 30 amino acidresidues of PRP-1 contain 13 of the 16 negatively
charged amino acids of the protein, including both
phosphoserines (Pse). From residue 31 to the COOHterminal end, the molecule essentially consists of
proline, glycine and glutamine with the peculiar
occurence of the sequence Pro-Gln-Gly-Pro-Pro
(Bennick, 1982; Hay et al., 1988). Consequently, the
role of the NH2-terminal portion of the molecule must
differ considerably from that of the COOH-terminal part.
These features have been extensively studied in terms
of structure-function
relationship.
Initial studies
performed on the various domains of PRPs showed
that the phosphoserine-containing amino-terminal 30residues are responsible for the inhibitory activity on
crystal growth. Inhibition of HAP-seeded crystal growth
by both PRPs and their NH2-terminal parts is closely
related to their capacity for adsorption onto crystal
surface (Hay et al., 1979; Bennick et al., 1979; Moreno
et al., 1979, 1982, 1984; Schlesinger and Hay, 1981;
Aoba et al., 1984). More complete experiments
revealed that dephosphorylation of the NH2-terminal
30-residues results in a sharp decrease of the

inhibitory activity (Hay et al., 1987). This is not simply
due to the charges of the phosphoserines since the
dipeptide PSe-PSe has no activity but rather to a
change in secondary structure resulting from
dephosphorylation (Aoba et al., 1984). Thus, the
structural basis of the inhibitory activity cannot be
merely limited to the role of residues. Other
experiments conducted with PRP-3 have shown that
the adsorption of the molecule onto crystal surface is
an endothermic process, driven by an increase of
entropy, i.e. a maximum disorder in its structure
(Moreno et al., 1982). This disorder can be translated
in terms of electrical charges, hydrophilicity and
distribution of these charges along the molecule. In
other words, these characteristics are derived from the
tridimensional structure of proteins which governs
interactions with the HAP growing surfaces, more than
the primary sequence of amino acid residues.
The cystatins.
Human cysteine proteinases are
involved in the intracellular catabolism of proteins.
They interact specifically with inhibitors called cysteine
proteinase inhibitors or cystatins. They represent a
superfamily divided into three families : type I is
represented by stefins essentially found within cells,
proteins of type II are found in several tissues and also
in biological fluids such as urine and saliva (Barrett,
1987), type Ill is the kininogen family present in blood
plasma. Type II cystatins contain about 115120 aminoacids, with two disulfide bridges in their
carboxy-terminal region. They were also designated as
cysteine-containing phosphoproteins (AI-Hashimi et
al., 1988). They include several sub-classes of
proteins : the acidic cystatins S1, S2 and S, previously
known as SAP-1 (lsemura et al., 1984). They were also
named C1-C3 by Shomers et al. (1982a). Cystatins S,
S1 and S2 are identical in amino acid composition and
N-terminal sequence. They probably differ only by their
degree of phosphorylation (Johnsson et al., 1991a;
lsemura et al., 1991). The Sand S1 forms are the most
abundant whereas S2 is very rare. The nonphosphorylated neutral cystatin SN (lsemura et al.,
1986) is very similar to the cystatin SA-I which shows
only an additional octapeptide in the NH2-terminal
region (AI-Hashimi et al., 1988). Cystatin SA-I
therefore appears to be a larger form of cystatin SN. It
is also the case with cystatin HSP-12 (SA-Ill; Lamkin
et al., 1991) which seems identical to cystatin S except
for the presence of a NH2-terminal octapeptide (Hawke
et al., 1987). It is quite probable that cystatin S and SN
resulted from proteolytic cleavage of cystatins HSP-12
and SA-I, respectively. Comparing amino acid
sequences of cystatins S, SA and SN revealed a very
high degree of similarity (around 90%; lsemura et al.,
1987). As for the other inhibitors in saliva, their
sequence was rather acidic in the NH2-terminal part
with a central region more basic. Yet, at variance with
the other inhibitors, their carboxy-terminal portion was
also acidic. Cystatins from type II bind strongly to HAP
(Shomers et al., 1982b). In addition, AI-Hashimi and
Levine ( 1989) detected in vivo the presence of
cystatin SN in the enamel pellicle. Using the dicalcium
phosphate dihydrate (DCPD) assay described by Hay
and Gron (1976), Shomers et al. (1982b) were able to
show that CCP (i.e., the C1, C2 and C3 forms) inhibited

1021

J.M.

Verdier, B. Dussol, Y. Berland, J.C. Dagorn

the transformation of DCPD crystals into basic calcium
phosphate salts. Johnsson et al. (1991 a) showed that
cystatins S, S1 and SN adsorbed to HAP with a
maximum about 30-50% of that found for statherin or
PRP-3, and with a lower affinity. The phosphorylation of
S into S1 does not seem to alter the affinity although
the phosphoserine-containing
cystatin S1 appears
more active in the inhibition of calcium phosphate
crystal growth than the two others, which are
themselves twice more active than statherin. In the
case of the S1 form, this could be explained by a better
binding to HAP since phosphocitrate, which is a potent
inhibitor of calcium phosphate crystal growth, strongly
adsorbs to HAP owing to its phosphate groups
(Johnsson et al., 1991b). It is not clear however how
molecules with low affinity for HAP (the S forms) might
present a lower Kd than a molecule with higher affinity
(the statherin). The larger size of the cystatins (around
120 amino acids), compared to that of statherin, might
permit binding at multiple sites and a stronger
adsorption.
The cystatin supeifamily appears as
complex. Diversity originates from multiple posttranslational modifications of precursors and from
expression of different genes. It should provide wider
specificity. For instance, some of the cystatins might be
involved in the prevention of dental-plaque aggression
by inhibiting bacterial cysteine proteinases (Obenauf et
al., 1984).
The hjstatjns. Histidine-rich-polypeptides (H RPs)
or histatins are components of the non-immune
defense system, which includes antibacterial and
antifungal activities (MacKay et al., 1984; Oppenheim
et al., 1986, 1988). As with cystatins, they were isolated
by several investigators leading to a certain confusion
in their nomenclature
(see Table 1 for the
concordance). One of the HRPs, histatin 1 (HRP), was
able to bind HAP (Oppenheim et al., 1986). It is a small
protein of 38 amino acids which differs from the other
characterized inhibitors by its pl, close to 7.0, and by its
low praline content. Usin~ a crystal growth assay,
Oppenheim et al. (1986) showed that it was an inhibitor
of crystal growth more potent than PRPs (between 1.5
and 6.5 times higher) but 6 times less active than
statherin (Hay et al., 1979; Oppenheim et al., 1986).
Moreover, it does not inhibit spontaneous precipitation
of calcium phosphate salts (Oppenheim et al., 1986).
Summary.
Praline-rich-proteins,
statherins,
cystatins and histidine-rich-polypeptides play a crucial
role in the maintenance of oral health by controlling the
precipitation of calcium phosphate salts onto dental
enamel. This activity is essentially localized in the NH2 terminal part of the proteins, at least for statherin and
the PRPs. The function of the carboxy-terminal region
is not known. However, adsorption results in the
presentation towards the oral cavity of basic amino
acids (or praline) which can bind lectin receptors
present at the surface of bacteria. For instance, PRPs
and statherin promote attachment to several important
bacterial strains as Actinomyces
viscosus
or
Bacteroides gingivalis. Consequently, the COOHterminal region should play a role in the control of
bacterial colonization of the teeth (Gibbons, 1980,
1989; Gibbons and Hay, 1988). Interaction of PRPs
and statherin with calcite was also evidenced. Some

salivary stones have been reported to contain mainly
calcite in dog and pig (Weaver, 1964; LeGeros and
Shannon, 1979). This led to the investigation of
macromolecular inhibitors of calcite precipitation in
human saliva. Proline-rich-proteins (Saitoh et al., 1985;
Hay et al., 1986) and statherin (Hay et al., 1986) were
found to be potential inhibitors of calcite nucleation. It
is, however, noteworthy that PRPs are not inhibitors of
CaP precipitation. What is the biological significance of
these results ? Inorganic phosphate is a potent
inhibitor
of primary
calcite precipitation.
Its
concentration in human saliva is much greater than
required in vitro to inhibit precipitation
from
supersaturated solutions (Hay et al., 1986). Thus, the
significance of PRPs and statherin as calcite inhibitors
in human saliva remains questionable. However, in
dogs, where the phosphate concentration is lower than
in humans and where calcite-containing calculi have
been found, inhibition of calcite precipitation by specific
proteins appears to be of more potential significance.
Inhibitors in bile
Bile contains large amounts of lipids which
include bile salts, phospholipids and sterols (Carey
and Cahalane, 1988), mainly cholesterol monohydrate.
It also contains bilirubin, a pigment present in the form
of bilirubinate conjugates (Fevery et al., 1983) and a
mixture of proteins (Swobodnik et al., 1991 ), mostly
from plasma such as albumin and lgA. Normal human
bile is always supersaturated
with respect to
bilirubinate calcium salts (Cahalane et al., 1988) and
may be supersaturated with respect to cholesterol
(Admirand and ~mall, 1968) and calcium carbonate
(Shiffman
et al., 1987). The control of these
supersaturated states therefore appears more complex
than in saliva or pancreatic juice. Bile salts and
phospholipids bind cholesterol so that it is maintained
in micellar solution (Admirand and Small, 1968). A
defect in the control would allow nucleation of
cholesterol or calcium carbonate crystals which would
lead to the formation of gallstones. In fact, the major
crystalline
phase found in most gallstones is
cholesterol (Sutor and Wooley, 1971 ), together with
bilirubinate/protein complexes and calcium carbonate
(CaCO3) or CaP (Bogren and Larsson, 1963; Been et
al., 1979; Malet et al., 1986; Palmer, 1987; Ostrow,
1990). Several constituents of bile are involved in the
stabilization of supersaturation,
i.e. inhibitors of
cholesterol precipitation (Holzbach et al., 1984; Busch
et al., 1991 ), CaCO3 (Sutor and Percival, 1978;
Sciaretta et al., 1984) and CaP (Sutor and Percival,
1976). These components are retained by membranes
with 1O kDa cut-off, suggesting that they are
macromolecules, among which proteins appear to
play a major role (eusch et al., 1991 ). For instance,
apolipoproteins A-I and A-II inhibit nucleation of
cholesterol in model systems of supersaturated bile
(Kibe et al., 1984). Since bile is also supersaturated in
CaCO3, some investigators have focused on the
existence of proteins controlling calcium carbonate
precipitation in bile.
Calcium-bindinc;i-protejn
(CB P)/C a lei umrec;iulatory protein (CRP\ L Anionic polypeptide fraction
.(Affl.
There are two main types of gallstones :
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a single protein (De Caro et al., 1979; Guy et al., 1983),
originally called the "pancreatic stone protein" (PSP).
The specific association of that protein with CaCO3
suggested that it could be the inhibitor involved in the
control of crystal growth, which was eventually
demonstrated (Scheele, 1984). The name "PSP"
turned out to be misleading, however (Multigner et al.,
1983), after large amounts of the protein had been
found in normal human pancreatic secretion. It was
recently changed to "lithostathine" with reference to the
protein capacity for inhibiting CaCO3 crystal growth
(Sarles et al., 1990). The first information on
lithostathine structure was obtained from the protein
extracted from stones (lithostathine C). Structure of the
secretory forms was established later and was
confirmed by data obtained from RNA sequencing.
Lithostathine C migrated as a single band on SDSPAGE, with an apparent molecular weight (Mr) of
15,000 (De Caro et al., 1984). Analysis of the protein
by isoelectric focusing revealed four bands in the
acidic region of the gradient (pl : 5.1, 5.3, 5.5 and 5.8),
indicating
charge heterogeneity.
Amino acid
composition of lithostathine C showed high contents in
acidic amino acids and the presence of three
phosphorylated residues. Sequence of 40 amino acids
from the amino-terminal end did not show homology
with other protein sequences available at the time. In
addition, antibodies raised to lithostathine C revealed
the presence of a related protein in normal pancreatic
juice but did not cross react with any other secretory
component. The same antibodies were used to
immunolocalize the protein in pancreas by electron
microscopy and showed a positive signal only in the
secretory compartments of acinar cells. Based on
immunological techniques, lithostathine therefore
appeared as a previously unrecognized component of
pancreatic secretion (Lechene de la Porte et al., 1986).
Lithostathine immunopurified from juice migrated as
five bands on SOS-PAGE, with Mr ranging from 15,000
to 19,000 (Montalto et al., 1986). The secretory forms of
the protein were called lithosthatine S and numbered
from 1 to 5 starting from the lowest Mr. The protein
represents 5-10% of total secretory protein (De Caro et
al., 1984). The secretory forms of the protein with a Mr
higher than 16,000 (lithostathines S2-s) could be
analyzed after separation from the S1 form (Mr=
15,000) by ion exchange chromatography. They had
the same protein backbone whose 144 amino acids
were sequenced (De Caro et al., 1987; 1989). Amino
acid composition was characterized by a high
percentage of Asp, Glu and Ser. Three disulphide
bridges were localized in positions 14-25, 42-140 and
115-132 (Rouimi et al., 1988). A complex glycan
containing fucose, galactose, mannose, N-acetyl
glucosamine, N-acetyl galactosamine and N-acetyl
neuraminic acid was linked to the threonine in position
5 (De Caro et al., 1989). The rest of the molecule was
apparently not glycosylated. Solubility of the S2-s forms
was above 1 mg/ml and was not notably affected by pH
in the 2.0-1 o.orange (De Caro et al., 1989; Gross et al.,
1985). The complete amino acid sequence. of
lithostathine S1 (133 residues) was also determined
(De Caro et al., 1989). It corresponded to the Cterminal end of the S2-s polypeptide, starting from the

cholesterol and black pigment stones. Both contain
calcium salts and a black polymer of derivatives of
bilirubin (Ostrow, 1990). CBP was purified from
cholesterol gallstones by Shimizu et al. (1989)
whereas CRP was purified from black pigment
gallstones (Okido et al., 1992). These small proteins
(less
than 6 kDa) have almost
identical
characteristics : they have a high content in acidic
(about 20% of aspartate and glutamate) and
hydrophobic (about 50%) amino acids residues and a
low content in basic residues (between 7 and 8%).
Moreover, both proteins are tightly bound to a pigment,
presumably bilirubin. This pigment, which is the final
product of heme catabolism, is conjugated with
carbohydrates, transported in the liver and excreted
into bile (Kuenzle et al., 1976). It protects lipids from
oxidation. This pigment cannot be fully dissociated
from the protein by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SOS-PAGE) or by
classical desalting procedures suggesting a covalent
binding as delta-bilirubin is to plasma albumin (Weiss
et al., 1983). CBP and CRP also present with the same
UV absorption spectrum. Both are inhibitors of CaCO3
precipitation (Shimizu et al., 1989; Okido et al., 1992)
and crystal growth (Okido et al., 1992), with similar
inhibitory parameters. These results strongly suggest
that they are closely related if not identical. It is
noteworthy that proteins act even in the presence of
bilirubin. The amino acid involved in the binding of the
pigment is assumed to be lysine (D. Ostrow, personnal
communication; Mir et al., 1992), a basic amino acid.
This suggests that the protein, which is amphipathic as
the other inhibitors of crystal growth, contains several
domains. The acidic part could be involved in the
control of crystal growth, whereas the basic domain
could be responsible for the binding of bilirubin and the
hydrophobic core would interact with lipids. Several
years ago, Martigne et al. (1985) reported the isolation
of an anionic polypeptide fraction (APF) from the
human gallbladder bile (Lafont et al., 1977). This
fraction consisted of a small polypeptide of about
6.5 kDa, highly acidic, and tightly bound to bilirubin. It
inhibited CaCO3 precipitation in vitro (Lafont et al.,
1991 ). APF was also detected in black pigment
gallstones (Martigne et al., 1988). Taken together these
results suggested that APF and CBP/CRP could be
related. Epitope mapping and immunological-cross
reactions actually confirmed that both proteins were
very similar if not identical (Domingo et al., 1992). APF
shared some epitopes with apolipoprotein A-1, a
protein present in bile in large amounts, which is an
inhibitor of cholesterol precipitation (Kibe et al., 1984).
APF/CBP interacts with cholesterol/lecithin vesicles
and promotes the nucleation of cholesterol from model
biles (Domingo et al., 1992). It is the first protein in bile
and gallstones reported to interact with calcium salts
and cholesterol, as an inhibitor or a promoter of
nucleation. Thus, it probably plays a key role in the
formation of both pigment and cholesterol gallstones.

The inhibitorof pancreatic
juice; lithostathine
The organic matrix associated with CaCO3 in
pancreatic stones obtained from patients presenting
with chronic calcifying pancreatitis is mostly made up of
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with a single Mr of 17,000. As in human, the native form
was very soluble and the S1 equivalent generated by
trypsin hydrolysis had much limited solubility at neutral
pH (Adrich et al., 1989). Molecular biology data
showed that human and rat lithostathines have the
same length and an overall amino acid identity of 70%
(Rouquier et al., 1991). Demonstration that lithostathine
is inhibitor of CaCO3 crystal growth in vitro (Multigner
et al., 1983; Yamadera et al., 1990; Bernard et al.,
1992) led to the hypothesis that the protein is involved
in the control of crystal growth in juice. As a
consequence, any circumstance leading to diminished
lithostathine activity is suspected to increase the risk for
stone formation into the ducts. In some patients
presenting chronic calcifying pancreatitis, one should
therefore
find
such
a decreased
activity.
Concentrations of lithostathine mRNA in the pancreas
of healthy individuals and patients presenting with
chronic calcifying pancreatitis were compared (Giorgi
et al., 1989). It was in average 2.3 times lower in
patients. In agreement with reduced synthesis,
immunolocalization
of lithostathine
in zymogen
granules by electron microscopy evidenced a reduced
signal in patients with chronic calcifying pancreatitis
(Lechene de la Porte et al., 1986). Decreased amounts
of lithostathine were also observed in the juice of
patients (Multigner et al., 1985; Provensal-Cheylan et
al., 1990) The messenger RNA encoding human prelithostathine was cloned from a pancreatic cDNA
library and sequenced (Giorgi et al., 1989). The 498
nucleotides of coding sequence corresponded to a
preprotein of 166 amino acids. Sequence of the mature
protein was found starting at residue 23, without
discrepancy with the sequence already determined.
The 22 N-terminal amino acids presented with the
structural features of signal peptides necessary for
exocrine proteins to enter the secretory pathway. The
organization of the lithostathine gene was established
by Watanabe et al. (1990). It spans approximately 3 kb
and is composed of 6 exons and 5 intrans.
Lithostathine is also expressed in tissues other than
the exocrine pancreas, in conditions where control of
crystal growth does not seem necessary such as
during dedifferentiation of colonic cells or regeneration
of pancreatic islets. The protein might therefore serve
another function which remains to be elucidated.

lie in position 12. Hence, lithostathine S1 derives from
lithostathine S2-s by trypsin-like hydrolysis of the Arglle bond in position 11-12 of the S2-s polypeptide
(Rouimi et al., 1987). Contrary to lithostathines S2-s,
solubility of the S1 form depends on pH. Below pH 4
and above pH 9.5, solubility is more than 1 mg/ml and
decreases to less than 0.1 mg/ml at neutral pH
(Montalto et al., 1986; Gross et al., 1985). When
lithostathine is purified from pancreatic juice collected
over a mixture of protease inhibitors, the S 1 form is
generally absent. The true secretory forms of
lithostathine
are therefore
the S2-s torms,
lithostathine S 1 being eventually formed in juice by
cleavage of the S2-s polypeptide. The polymorphism of
the S2-s forms remains to be explained. Cloning and
sequencing the lithostathine mRNA confirmed that the
protein was encoded by a single transcript and that the
amino acid sequence of the encoded protein was
identical to the sequence previously determined for the
S2-s polypeptide (Giorgi et al., 1989). These results
suggested that polymorphism of the S2-s forms was
caused by post-translational maturation of a single
polypeptide. Involvement in polymorphism of the
glycan borne by the NH2-terminal peptide was
demonstrated (De Caro et al., 1989). The biological
significance of the polymorphism remains obscure.
Demonstration that CaCO3, the constituent of stones,
was in supersaturated
concentration
in normal
pancreatic juice led to the corollary that an inhibitor of
CaCO3 crystal growth had to be present in juice. Such
an inhibitor must interfere with crystal nucleation or
growth. The interaction of lithostathine with both steps
was studied in vitro (Bernard et al., 1992).
Lithostathines S2-s did inhibit nucleation, a significant
effect being already observed at a concentration of
1.5 µM (30 µg/ml). Neither the S1 form nor albumin or
other secretory proteins showed any inhibition.
However, lithostathine S2-s at a concentration of
1.5 µM significantly inhibited CaCO3 crystal growth,
contrary to the other pancreatic proteins tested. Binding
to crystal growth sites occured with a Kd= 0.9 x 10-6 M.
The S1 form being inactive, it was very likely that the Nterminal undecapeptide was involved in inhibition. In
fact, the purified peptide was active, with a Kd= 3.1 x
10-6 M for growth sites, very similar to the Kd of the
complete molecule. Activity was abolished by treatment
of the polypeptide with the V8 protease. The 11
aminoacids of the N-terminal end of lithostathine
therefore contain the entire inhibitory site. The complex
glycan linked to the threonine in position 5 of that
peptide is not involved in the active site since a
synthetic undecapeptide identical to the natural one
but not glycosylated was equally active (Bernard et al.,
1992). Antibodies to human lithostathine could detect
the presence of related components in the pancreatic
juice or homogenate of other mammals including rat,
dog, cow, monkey and pig (Bernard et al., 1991).
Inhibitory activity was demonstrated in dog and rat. The
rat protein was studied in more detail and compared to
human lithostathine (Adrich et al., 1989). The structures
of the N-terminal peptides were very similar and an
Arg-lle bond was also present in position 11-12 of the
native molecule. The rat peptide was however not
glycosylated and the protein migrated on SOS-PAGE

Conclusions
Most studies regarding protein inhibitors of crystal
growth have underscored their amphipathic structure.
All of them are organized into hydrophilic and
hydrophobic domains. The charged acidic region
possesses an affinity for the charged crystal and tends
to coat its surface, whereas the hydrophobic region,
oriented towards the solution, prevents crystal
overgrowth. This mechanism seems to apply to all
proteins inhibiting calcium salts precipitation. Crystal
growth can nevertheless occur in some instances. A
qualitative or quantitative defect (Dagorn, 1992) as
shown for calcium nephrolithiasis (Nakagawa et al.,
1985), might be the main factor in the development of a
lithiasis. It might also result from an imbalance between
promoters
and inhibitors,
resulting
from an
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inhibition of different crystal habits of the same salt. For
instance, the structure of calcite shows alternate layers
of calcium and carbonate ions, aligned perpendicularly
to the c-axis. If the distance between two calcium atoms
from the crystal fits with the distance between
carboxylic groups of acidic residues from the protein,
the oxygen atoms can interact with calcium ions and
prevent further juxtaposition of earbonate ions by
disrupting the correct organization. The whole structure
of the crystal will therefore be highly affected (Weiner
and Addadi, 1991 ). In fact, studies conducted with
nephrocalcin, the inhibitor of calcium oxalate crystal
growth from urine (Nakagawa et al., 1983), have
shown that the interaction between nephrocalcin and
calcium oxalate monohydrate crystals resulted also in
a disturbance of ion stacking along the c-axis by
binding to the {-1,0, 1} face and disturbing the
juxtaposition
of {-1,0, 1} layers along this axis
(Deganello, 1991 ). Therefore, it seems that all
inhibitors interact with crystals by similar mechanisms.
Many aspects of the control of crystal growth are
still unresolved and represent an exciting challenge for
the future. Mechanisms of molecular recognition of
inorganic surfaces by organic compounds and
resolution of tridimensional
structures of these
inhibitors should provide important clues to the
understanding of the processes of crystal growth
control.

overproduction of promoters or a deficiency in
inhibitors. Recent studies have shown that bile
contains proteins promoting the formation
of
cholesterol crystals (Burnstein et al., 1983; Levy et al.,
1984; Gallinger et al., 1985; Groen et al., 1988; Busch
et al., 1991 ). In saliva, dentin, a very acidic
phosphoprotein (Veis and Perry, 1967), promotes the
formation of HAP (Nawrot et al., 1976). Another
possibility, observed in human urine with the TammHorsfall protein (Tamm and Horsfall, 1950), is that a
protein can either promote or inhibit crystal growth or
aggregation, depending on physiological conditions
(Yoshioka et al., 1989; Grover et al., 1990; Hess, 1992).
All these examples demonstrate the complexity of the
situation in vivo and the necessity for an adequate
equilibrium
between promoters and inhibitors.
Characteristics common to these inhibitors are not
restricted to mammals. The organic matrix of all
mineralized tissues, including mollusk shells or
arthropods (Duman and Horwath, 1983; Weiner, 1986),
contain proteins with a hydrophilic domain very rich in
aspartate, which inhibit crystal growth (Weiner, 1979).
For instance, antifreeze proteins, produced by many
polar and northern coastal fishes during the winter
season, inhibit ice crystal growth. When the
temperature
reaches two degrees below zero,
adaptation
to external
conditions
maintains
homeostasis by lowering the freezing point of body
fluids and preventing lethal freezing injury (for a review
see Devries, 1983). Some of them, but not all, have a
structure different from that of mammalian inhibitors.
They are too small to be organized into domains, and
are rich in alanine residues. Surprisingly, alanine
residues have a strong tendency to form an a-helix in
water (Chakrabartty et al., 1991) so that they present ahelical structures in vivo with partial amphiphily (Yang
et al., 1988). This a-helix shows a dipole moment
parallel to the helix axis. Interactions of these dipoles
with those of the water (dipole-dipole interaction)
inhibit the growth of ice nuclei (Shoemaker et al.,
1987). This is reminiscent of the putative a-helix of the
acidic NH2-terminal of statherin and suggests that
inhibitory function cannot be inferred from primary
sequence analysis only. This is further supported by
the amino acid comparisons
performed
with
mammalian proteins. The mechanisms involved in the
different systems of crystal growth control are
apparently similar. Yet, amino acid sequences
available for the inhibitors do not show any particular
similarity, suggesting that tridimensional structure is
probably of paramount importance. Another element of
complexity results from the variety of crystal forms for a
single product, depending on its atomic organization.
For instance, calcium carbonate can crystallize in three
different systems, with formation of calcite, aragonite or
vaterite, all of them present in animals. We have
demonstrated that pancreatic lithostathine could inhibit
crystal growth of vaterite and calcite (J.M. Verdier,
unpublished). Experiments done with statherin and
PRPs showed that they were able to inhibit nucleation
of calcium carbonate and calcium phosphate salts.
These results suggest that inhibitors are generally not
specific and that their structure is compatible with the
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Discussionwith Reviewers

J.P.

Binette: Do the two lithostathine C and S have
reaction of identity? The text says "related". Is there any
difference between the two?
Authors: Lithostathine C and S are apparently identical
molecules. The distinction was originally made on the
basis of localization (lithostathine C in stones,
lithostathine S as a product of trypsine hydrolysis in
pancreatic juice).

J,P,

Binette: Would the authors agree to display their
sagacity and comment on the role of the matrix?
Authors: This has been well studied in our lab for
pancreatic lithostathine, which can be inhibitor or
promotor of crystal growth, depending on the integrity
of the molecule. The intact protein is inhibitor of crystal
growth. Yet, upon trypsin hydrolysis, the N-terminal
undecapeptide (bearing the inhibitory activity) is
cleaved and the rest of the molecule precipitates at
neutral pH in the form of fibrils. These precipitates grow
until complete obstruction of the pancreatic ducts,
whose epithelium becomes eroded. The resulting
transsudation increases locally the Ca2+ concentration
and the protein plugs promote apposition of CaCO3
crystals. The process ends with the formation of a
crystalline shell around the plug.

S, Deganello: Why do you state that inhibitors are not
specific? Are you not, perhaps, comparing inhibition
conditionsq which require similar stereochemical
interactions?
Authors: We think that inhibitors recognize a specific
stereochemistry and not a given crystal. In these
conditions, a given inhibitor can bind different forms of
the same crystal (e.g., vaterite and calcite for CaCO3
crystals) or even crystals coming from different salts if
they present with similar 3D structures.

S. Deganello: Recent structural data demonstrate that
THP does not inhibit the growth of COD. According to
you, under what atomic-molecular conditions could the
behavior of THP be reversed to that of an inhibitor? Is
this likely to happen? If so, why?
Authors;
We agree with these data. Recent
unpublished observations of two groups (including
ours) seem to corroborate these results, but keeping in
mind the findings of 8. Hess, the situation concerning
THP remains questionnable. Sorry, but we do not have
a clear idea.
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